COMMUNIQUÉS West-GlobeNewswire

IBA signs contract with the Government of Assam for India’s First State-run Proton Therapy Center
05/11/2026
The project in Assam marks an important milestone in expanding access to advanced cancer care in India Louvain-La-Neuve, Belgium, November 05, 2026 at 7 a.m. CET – IBA (Ion Beam Applications S.A., EURONEXT), the world [...]
Q3 2026 Update: Tecan reports acceleration of sales growth in Q3 and raises full-year 2026 outlook
05/11/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q3 2026 Update: Tecan reports acceleration of sales growth in Q3 and raises full-year 2026 outlook Männedorf, Switzerland, November [...]
Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
05/11/2026
Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update Ongoing negotiations with different parties towards securing a partnership or financing for the development of varoglutamstat in [...]
Siemens Healthineers to Rebrand In Vitro Diagnostics Business as Olyrian Diagnostics
05/11/2026
Siemens Healthineers announced today it has initiated the carve-out process for its in vitro diagnostics business Tarrytown, New York, USA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- The company is preparing its Diagnostics [...]
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
05/11/2026
Egetis Therapeutics’ lead asset, EMCITATE ® , is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, a rare genetic disorder, impacting approximately 1 [...]
Interim report 9M 2026
05/11/2026
Strong Q3 sales leading to 9M at 7% organic sales growth and adj. EBITDA margin of 37.9%. 2026 outlook confirmed: 7-8% organic sales growth and adj. EBITDA margin at the higher end of the 37-38% range. Ester Baiget, [...]
T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease
05/11/2026
$133 million Series B financing co-led by new investors Advent Life Sciences and British Business Bank, with additional new investments from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Samsara BioCapital, M- [...]
9M 2026: Novonesis delivered 7% organic sales growth, confirming full-year outlook
05/11/2026
COPENHAGEN, Denmark – November 5, 2026. Novonesis delivered strong Q3 sales leading to 9M financial results at 7% organic sales growth and adjusted EBITDA margin of 37.9%. In addition, our 2026 outlook is confirmed at 7 [...]
Ethris Reports Positive Topline Phase 2a Data for Nasal mRNA Candidate ETH47 in Asthma Patients Challenged with Rhinovirus
05/11/2026
40-fold lower virus load compared to placebo on Day 2, at the peak of viral replication Exposure-response relationship observed, with greater interferon lambda (IFNλ) exposure associated with greater antiviral and [...]
Alethio Therapeutics Raises $90 Million (£67 Million) in Oversubscribed Series A Financing to Advance a New Generation of Therapies for Myeloproliferative Neoplasms
05/11/2026
Series A financing co-led by Sofinnova Partners and RA Capital alongside founding investor Oxford Science Enterprises with support from Cancer Research Horizons and the University of Oxford, bringing together a world- [...]
ArrayPatch Completes Oversubscribed €3.2 Million Seed Financing to Advance Next-Generation Microneedle Therapeutics
05/11/2026
CORK, Ireland, Nov. 05, 2026 (GLOBE NEWSWIRE) -- ArrayPatch Ltd (“ArrayPatch”), a biotech company developing innovative microneedle-based therapeutics, today announced the successful completion of the second close of [...]
ArrayPatch boucle un tour de financement d’amorçage sursouscrit de 3,2 millions d’euros pour faire progresser ses traitements par micro-aiguilles de nouvelle génération
05/11/2026
CORK, Irlande, 05 nov. 2026 (GLOBE NEWSWIRE) -- ArrayPatch Ltd (« ArrayPatch »), une société de biotechnologie développant des traitements novateurs à base de micro-aiguilles, a annoncé aujourd’hui la clôture réussie de [...]
Link Biologics completes IND-enabling preclinical programme for LB001, a first-in-class novel therapy for dry eye disease
05/11/2026
Completion of key IND-enabling activities represents a major development milestone for LB001 IND submission remains on track for Q1 2027, followed by initiation of a Phase 1/2 clinical study Manufacturing scale-up [...]
Interim Report Q3 2026: Successful product launches leading to 2% organic revenue growth and margin expansion
05/11/2026
Highlights The Enterprise division delivered organic revenue growth of 1%, following positive market reception of the second wave of the Evolve3 launch. The development reflects continued solid performance in North [...]
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
05/11/2026
— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval — — Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent designation for primary [...]
TaiMed Biologics to Present 24-Week Phase 2a Data on TMB-365/TMB-380 Maintenance Regimen at HIV Glasgow 2026
05/11/2026
Company will present results from a Phase 2a study of TMB-365/TMB-380 administered every eight weeks as maintenance therapy in virologically suppressed people living with HIV-1, along with an encore poster on its Phase [...]
Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
05/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it hosted a key opinion leader webinar this [...]
Step Pharma to present data from ongoing phase 2 clinical trial of dencatistat in essential thrombocythaemia at 68th ASH Annual Meeting
05/11/2026
First presentation of clinical data from ET programme demonstrating a consistent and clinically meaningful platelet control with favourable tolerability profile VECTRA trial will enrol up to 50 participants with high- [...]
Cloudbreak Pharma Announces Top-Line Results from its Phase 3 Study of CBT-001 in Patients with Pterygium
05/11/2026
Both doses of CBT-001 demonstrated statistically significant improvements in conjunctival hyperemia at Month 3 versus vehicle (p<0.001), with improvement observed as early as Week 2 and maintained through Month 12 [...]

Pages